IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Statin, Beyond Hyperlipidemia toward a Novel Agent for Hepatitis C & Authors' Reply

AUTHORS

Mahmoud Khattab 1 , * , Mohammed Eslam 1 , Michele Malaguarnera 2 , Maria Giordano 2 , Cristina Russo 2 , Mariano Malaguarnera 3 , Fabio Galvano 2 , Giovanni Volti 2

AUTHORS INFORMATION

1 Department of Internal Medicine, Minia University, Minia, Egypt

2 Department of Biochemistry, Medical Chemistry and Molecular Biology, University of Catania, Catania, Italy

3 Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy

ARTICLE INFORMATION

Hepatitis Monthly: 11 (9); e93019
Published Online: September 20, 2011
Article Type: Letter
Received: May 06, 2019
Accepted: May 06, 2011

Crossmark

CHEKING

READ FULL TEXT
Abstract

Dear Editor,
We read with great interest the article by Malaguarnera et al. (1) in this issue of Hepatitis monthly, in which the safety and efficacy of rosuvastatin plus interferon and ribavirin were evaluated in a randomized controlled trial. Sustained viral response was observed in 40% of the standard-care group and 51% of the triple-therapy group, and this was associated with improvement of steatosis and fibrosis without causing side effects. Despite the importance of this study, we think that the clinical implications extracted from this study deserve further evaluation. In particular, we question some components of the study design.

Keywords

Hepatitis C Statin Sustained virological response

© 2011, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Fulltext
References
  • 1. The references are available in the PDF file.
  • COMMENTS

    LEAVE A COMMENT HERE: